Metraipolis › archive › dc_d4bed4245836

Cost-effectiveness of apixaban vs. aspirin for the reduction of thrombo-embolism in high-risk patients with device-detected atrial fibrillation: insights from… — Europe PMC PMID:40886070

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/40886070
DOI
10.1093/europace/euaf195
License (as archived)
solo-consultazione
Archived
2026-11-10T05:02:37.526Z
SHA-256 of the archived text
18d0bd674994ce5bc8228ce3b117667ac3ffff0e575dc5543d25ba101917c451
Stable URL of this page
https://metraipolis.com/documento/dc_d4bed4245836

How to cite

Cost-effectiveness of apixaban vs. aspirin for the reduction of thrombo-embolism in high-risk patients with device-detected atrial fibrillation: insights from… — Europe PMC PMID:40886070 — Europe PMC (en), https://europepmc.org/article/MED/40886070 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_d4bed4245836 (Metraipolis archive dc_d4bed4245836, sha256 18d0bd674994ce5bc8228ce3b117667ac3ffff0e575dc5543d25ba101917c451)
BibTeX
@misc{dcd4bed4245836,
  title = {Cost-effectiveness of apixaban vs. aspirin for the reduction of thrombo-embolism in high-risk patients with device-detected atrial fibrillation: insights from… — Europe PMC PMID:40886070},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40886070},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_d4bed4245836; sha256 18d0bd674994ce5bc8228ce3b117667ac3ffff0e575dc5543d25ba101917c451},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40886070. Agents can read the archived copy with the MCP tool read_document.